Compare IMU which has 4 clinical trials (3 X phase 1A and 1 X Phase 1B) and CHM (3 X Phase 1B and 1 X Phase 1A) and CHM is massively undervalued.
IMU has an enterprise value of $420m versus CHMs $10m….CHM is crazy good value and I would say the pipeline is superior to IMU. Go figure.
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment, page-7
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.18M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.8¢ | 1.6¢ | $46.18K | 2.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1837328 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 153426 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |